MCK — McKesson Corporation

As of 2026-09-13 the sell-side is firmly constructive: 25 Buy/Strong Buy ratings against 6 Holds and zero Sells, with an FMP consensus price target of $953 (recent average $948.25) and the live brief citing street targets in the $973-$1,000 range after Citi raised to $1,000 and Baird reiterated $1,015. The catalysts behind that tone are dated and recent: the Q1 FY27 print on 2026-08-05 ($105.38B revenue, +7.7% YoY, adjusted EPS $9.93, full-year midpoint guidance raised ~1%), a 15% dividend hike to $0.94/quarter announced 2026-07-22, and the Precision Medicine Group acquisition signed 2026-08-25. The tape broadly agrees - the stock is +12.43% over three months - though it has given back 2.92% in the last week and is still -6.31% over six months, so this is a quiet, fundamental-driven bullishness rather than momentum froth.

The top line is clearly decelerating while margins inflect the other way. Revenue YoY went from +23.4% (Jun-2025 quarter), +21.3% (Sep-2024), +17.8% (Dec-2024) and +19.0% (Mar-2025) down to +10.1% (Sep-2025), +11.4% (Dec-2025), +6.0% (Mar-2026) and +7.7% (Jun-2026, $105.38B) - mid-to-high single digits now versus low-20s a year ago. Margins are moving the opposite direction, and consistently: operating margin was 1.25% in the Jun-2026 quarter vs 1.06% a year earlier, 2.34% vs 1.14% in Mar-2026, 1.53% vs 1.35% in Dec-2025, and 1.42% vs 0.80% in Sep-2025 - four consecutive quarters of YoY expansion. Cash flow remains lumpy and highly seasonal (the March quarter is the big positive, the June quarter negative on working capital), but trailing-four-quarter FCF of $6.185B is up ~9% on the prior four-quarter stretch of $5.666B. The one blemish: the Jun-2026 quarter's GAAP diluted EPS of $5.15 is well below the $9.93 adjusted figure, a wide GAAP-to-adjusted wedge that needs watching. Net read: decelerating revenue, expanding margin, stable-to-growing cash - a mix-shift story, not a deterioration.

Fairly valued to modestly cheap versus its own history, not cheap in absolute terms. As of 2026-09-13 the stock carries a 23.49x trailing P/E against its own 25.65x five-year average - roughly an 8% discount - and trades at ~19.8x the $44.63 next-FY EPS estimate. P/S of 0.251 is above the 0.22 five-year average, so the discount is earnings-specific, not broad-based. The reported PEG of 0.479 looks anomalous and implies ~49% earnings growth; do not take that at face value - MCK's realistic adjusted EPS growth cadence is mid-teens, which implies a forward PEG nearer 1.3x. EV/EBITDA of 15.6x and a ~0.43% forward dividend yield (the data feed's 0.375% still reflects the pre-hike $0.82 payout) round out a picture of a premium-quality, low-beta (0.307) defensive name priced at a market-like multiple.

Here is the key tension: at $881.51 the market is paying ~19.8x next-FY EPS of $44.63, which embeds roughly 15% earnings growth over trailing EPS of ~$38.7 - but consensus revenue for the next fiscal year is $431.96B versus $410.98B trailing, only ~5% growth. In other words, essentially all of the expected EPS growth has to come from margin mix (specialty/oncology/biopharma services) and share count reduction, not from volume/value growth. That is achievable - MCK has been doing exactly that - but it leaves no room for a stumble, and it explains why the multiple has drifted below the five-year average. Also remember the GAAP-versus-adjusted split: headline P/E of 23.5x sits well above the ~19.8x adjusted forward P/E, so an investor needs to be explicit about which earnings stream they are underwriting. With the street's $948-$953 targets implying only ~8% upside, the stock is priced roughly at fair value with execution risk skewed to the downside on any guidance miss.

As of 2026-09-13, RSI(14) sat at 50.62 - dead neutral, neither overbought nor oversold. Price of $881.51 was -0.39% versus the 20-day SMA (implied ~$885), +2.81% versus the 50-day (~$857) and +4.47% versus the 200-day (~$844). Return profile: -2.92% over one week, +0.32% over one month, +12.43% over three months, -6.31% over six months. Read: a three-month recovery rally off the spring lows that has stalled in the last week and is consolidating just under its short-term average while holding above the medium- and long-term ones - a mild uptrend in a range. There is no timing urgency here. The $844-$857 zone (200-day/50-day) is the line in the sand; a decisive break below it would signal the rally has failed, while a push back above ~$900-$905 would re-open the path toward the $999 52-week high.

• Drug-pricing politics and PBM reform: wholesalers earn largely fee- or percentage-based spread, which limits direct exposure, but persistent legislative noise around list prices and supply-chain transparency caps the multiple the market is willing to pay.
• Specialty, oncology and GLP-1 mix shift: rapid growth in high-cost specialty and anti-obesity drugs inflates revenue and pushes mix toward higher-margin biopharma services, partially offsetting the 3.6% gross margin reality of core distribution.
• Demographics: an aging population and rising chronic-disease burden provide a durable, low-cyclicality volume tailwind - MCK's beta of 0.307 confirms the market treats this as a defensive holding.
• Interest rates: a moderating rate backdrop lowers borrowing costs for a company carrying $8.43B of long-term debt and funding both a buyback program and M&A (Precision Medicine Group), improving balance-sheet flexibility versus the peak-restrictive cycle.
• Generic deflation and medical-surgical cost/tariff pressure: on a 3.6% gross margin, small changes in generic pricing or landed product costs flow almost directly to operating profit.

• Q2 FY27 earnings on 2026-11-04 (consensus EPS ~$10.75) - the first real test of whether the ~1% full-year guidance raise holds and whether the four-quarter margin expansion streak continues.
• Execution on the announced Precision Medicine Group acquisition (2026-08-25) and any update on the planned medical-surgical business separation, both of which could re-rate the multiple if they shift mix toward higher-margin services.
• Continued capital return: the 15% dividend hike to $0.94/quarter plus ongoing accelerated share repurchases shrink the share count and mechanically support mid-teens EPS growth on ~5% revenue growth.
• Any Washington action (or relief) on drug pricing and PBM transparency, which would move the whole distribution group's multiple.

• The multiple now depends on ~15% adjusted EPS growth against only ~5% revenue growth; if margin mix or buyback pace slows, the stock re-rates down without any revenue miss.
• Earnings quality: Q1 FY27 GAAP diluted EPS of $5.15 versus $9.93 adjusted is a very wide gap - recurring one-off charges would undercut the adjusted-earnings story investors are paying for.
• Balance-sheet optics are structurally thin: stockholders' equity was -$4.24B at 2026-06-30, total current liabilities ($70.36B) exceed total current assets ($62.84B), and the current ratio is 0.893 with a quick ratio of 0.52 - normal for the model, but leaving little slack if working capital or credit conditions tighten.
• Customer and manufacturer concentration in a business where a single large retail or health-system contract loss moves the needle; 3.6% gross margin leaves minimal cushion for repricing.
• Regulatory/political intervention on drug pricing, plus integration and execution risk on both the pending medical-surgical separation and the newly announced Precision Medicine Group deal.

McKesson is a genuinely high-quality, low-beta healthcare compounder - 31.5% ROIC, four straight quarters of YoY operating-margin expansion, $6.19B of trailing free cash flow growing ~9% YoY, a freshly raised dividend and a persistent buyback - but it is not a bargain at $881.51 as of 2026-09-13. At ~19.8x forward adjusted EPS the market is already paying for mid-teens EPS growth on mid-single-digit revenue growth, and the street's ~$948-$953 target implies only high-single-digit upside. I would be a holder rather than a buyer at this price: the risk/reward is balanced, and a pullback toward the 200-day area (~$844) or concrete evidence that margin expansion is durable into FY28 would make it a materially better entry.

I applied a 21.5x multiple to the $44.63 next-FY (FY27, ending March 2027) consensus EPS, deliberately between the current forward P/E of 19.75x and the five-year average trailing P/E of 25.65x to reflect a durable low-beta franchise with expanding margins but decelerating revenue growth and drug-pricing regulatory overhang: 44.63 x 21.5 = $959.5, rounded to $960. I cross-checked with a normalized free-cash-flow yield - trailing-four-quarter FCF of $6.185B over ~117.1M shares is ~$52.83/share, and a 5.5% required FCF yield gives ~$961, consistent with the multiple-based figure and sitting modestly above the FMP consensus target of $953.